首页 > 最新文献

Experimental and Molecular Medicine最新文献

英文 中文
A dual inhibitor of PIP5K1C and PIKfyve prevents SARS-CoV-2 entry into cells PIP5K1C 和 PIKfyve 的双重抑制剂可阻止 SARS-CoV-2 进入细胞。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01283-2
Yuri Seo, Yejin Jang, Seon-gyeong Lee, Joon Ho Rhlee, Sukyeong Kong, Thi Tuyet Hanh Vo, Myung hun Kim, Myoung Kyu Lee, Byungil Kim, Sung You Hong, Meehyein Kim, Joo-Yong Lee, Kyungjae Myung
The SARS-CoV-2 pandemic has had an unprecedented impact on global public health and the economy. Although vaccines and antivirals have provided effective protection and treatment, the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells. UNI418 inhibited the proteolytic activation of cathepsins, which is regulated by PIKfyve, resulting in the inhibition of cathepsin L-dependent proteolytic cleavage of the SARS-CoV-2 spike protein into its mature form, a critical step for viral endosomal escape. We also demonstrated that UNI418 prevented ACE2-mediated endocytosis of the virus via PIP5K1C inhibition. Our results identified PIKfyve and PIP5K1C as potential antiviral targets and UNI418 as a putative therapeutic compound against SARS-CoV-2. The COVID-19 pandemic, triggered by the SARS-CoV-2 virus, underscores the immediate need for effective treatments, particularly for severe cases. Even with vaccines, treatments that block the virus’s entry into cells are vital. SARS-CoV-2 enters host cells by attaching to the ACE2 receptor, a process that is a prime target for intervention. This research concentrates on blocking the virus’s entry into cells as a potential treatment method. The study is an experiment using cellular models to assess the effectiveness of a new compound, UNI418, in preventing SARS-CoV-2 infection. UNI418 targets enzymes involved in cell membrane dynamics, essential for the virus’s entry. The researchers conclude that UNI418, by blocking PIP5K1C and PIKfyve, offers a promising approach to preventing SARS-CoV-2 infection and emphasizes the importance of targeting the virus’s entry process as a treatment strategy. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
SARS-CoV-2 大流行对全球公共卫生和经济造成了前所未有的影响。尽管疫苗和抗病毒药物提供了有效的保护和治疗,但要改善 SARS-CoV-2 的临床治疗效果,开发新的小分子抗病毒候选药物势在必行。在这项研究中,我们发现 UNI418(一种 PIKfyve 和 PIP5K1C 双重抑制剂)是一种能抑制 SARS-CoV-2 进入宿主细胞的新型化学制剂。UNI418 可抑制由 PIKfyve 调节的蛋白酶的蛋白水解活化,从而抑制依赖于蛋白酶 L 的蛋白水解作用,将 SARS-CoV-2 穗状病毒蛋白裂解为成熟形式,这是病毒内体逃逸的关键步骤。我们还证明,UNI418 通过抑制 PIP5K1C 阻止了 ACE2 介导的病毒内吞。我们的研究结果将 PIKfyve 和 PIP5K1C 确定为潜在的抗病毒靶点,并将 UNI418 确定为一种可治疗 SARS-CoV-2 的化合物。
{"title":"A dual inhibitor of PIP5K1C and PIKfyve prevents SARS-CoV-2 entry into cells","authors":"Yuri Seo, Yejin Jang, Seon-gyeong Lee, Joon Ho Rhlee, Sukyeong Kong, Thi Tuyet Hanh Vo, Myung hun Kim, Myoung Kyu Lee, Byungil Kim, Sung You Hong, Meehyein Kim, Joo-Yong Lee, Kyungjae Myung","doi":"10.1038/s12276-024-01283-2","DOIUrl":"10.1038/s12276-024-01283-2","url":null,"abstract":"The SARS-CoV-2 pandemic has had an unprecedented impact on global public health and the economy. Although vaccines and antivirals have provided effective protection and treatment, the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells. UNI418 inhibited the proteolytic activation of cathepsins, which is regulated by PIKfyve, resulting in the inhibition of cathepsin L-dependent proteolytic cleavage of the SARS-CoV-2 spike protein into its mature form, a critical step for viral endosomal escape. We also demonstrated that UNI418 prevented ACE2-mediated endocytosis of the virus via PIP5K1C inhibition. Our results identified PIKfyve and PIP5K1C as potential antiviral targets and UNI418 as a putative therapeutic compound against SARS-CoV-2. The COVID-19 pandemic, triggered by the SARS-CoV-2 virus, underscores the immediate need for effective treatments, particularly for severe cases. Even with vaccines, treatments that block the virus’s entry into cells are vital. SARS-CoV-2 enters host cells by attaching to the ACE2 receptor, a process that is a prime target for intervention. This research concentrates on blocking the virus’s entry into cells as a potential treatment method. The study is an experiment using cellular models to assess the effectiveness of a new compound, UNI418, in preventing SARS-CoV-2 infection. UNI418 targets enzymes involved in cell membrane dynamics, essential for the virus’s entry. The researchers conclude that UNI418, by blocking PIP5K1C and PIKfyve, offers a promising approach to preventing SARS-CoV-2 infection and emphasizes the importance of targeting the virus’s entry process as a treatment strategy. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1736-1749"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01283-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cholesterol imbalance and neurotransmission defects in neurodegeneration 胆固醇失衡与神经变性中的神经传递缺陷
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01273-4
Kyung Chul Shin, Houda Yasmine Ali Moussa, Yongsoo Park
The brain contains the highest concentration of cholesterol in the human body, which emphasizes the importance of cholesterol in brain physiology. Cholesterol is involved in neurogenesis and synaptogenesis, and age-related reductions in cholesterol levels can lead to synaptic loss and impaired synaptic plasticity, which potentially contribute to neurodegeneration. The maintenance of cholesterol homeostasis in the neuronal plasma membrane is essential for normal brain function, and imbalances in cholesterol distribution are associated with various neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. This review aims to explore the molecular and pathological mechanisms by which cholesterol imbalance can lead to neurotransmission defects and neurodegeneration, focusing on four key mechanisms: (1) synaptic dysfunction, (2) alterations in membrane structure and protein clustering, (3) oligomers of amyloid beta (Aβ) protein, and (4) α-synuclein aggregation. Cholesterol, a substance crucial for the brain, can lead to diseases like Alzheimer’s and Parkinson’s when imbalanced. This review investigates how this imbalance causes brain cell degeneration, focusing on issues like communication breakdown and harmful protein build-up. The study combines findings from different experiments to understand cholesterol’s role in the brain. The review emphasizes the need for cholesterol balance for brain health and identifies potential treatment targets for neurodegenerative diseases. The main findings suggest that cholesterol imbalance disrupts brain cell communication and leads to harmful protein build-up, causing brain cell degeneration. The researchers conclude that focusing on cholesterol metabolism and distribution could lead to new treatments for these conditions. Future research may lead to treatments that correct cholesterol imbalances, possibly slowing or preventing neurodegenerative diseases. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
人体内胆固醇含量最高的部位是大脑,这凸显了胆固醇在大脑生理学中的重要性。胆固醇参与神经发生和突触生成,与年龄相关的胆固醇水平降低会导致突触丢失和突触可塑性受损,从而可能导致神经退化。维持神经元质膜中胆固醇的平衡对大脑的正常功能至关重要,而胆固醇分布的失衡与阿尔茨海默病、帕金森病和亨廷顿病等多种神经退行性疾病有关。本综述旨在探讨胆固醇失衡导致神经传导缺陷和神经退行性病变的分子和病理机制,重点关注以下四种关键机制:(1) 突触功能障碍;(2) 膜结构和蛋白质聚类的改变;(3) 淀粉样 beta(Aβ)蛋白的寡聚体;(4) α-突触核蛋白的聚集。
{"title":"Cholesterol imbalance and neurotransmission defects in neurodegeneration","authors":"Kyung Chul Shin, Houda Yasmine Ali Moussa, Yongsoo Park","doi":"10.1038/s12276-024-01273-4","DOIUrl":"10.1038/s12276-024-01273-4","url":null,"abstract":"The brain contains the highest concentration of cholesterol in the human body, which emphasizes the importance of cholesterol in brain physiology. Cholesterol is involved in neurogenesis and synaptogenesis, and age-related reductions in cholesterol levels can lead to synaptic loss and impaired synaptic plasticity, which potentially contribute to neurodegeneration. The maintenance of cholesterol homeostasis in the neuronal plasma membrane is essential for normal brain function, and imbalances in cholesterol distribution are associated with various neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. This review aims to explore the molecular and pathological mechanisms by which cholesterol imbalance can lead to neurotransmission defects and neurodegeneration, focusing on four key mechanisms: (1) synaptic dysfunction, (2) alterations in membrane structure and protein clustering, (3) oligomers of amyloid beta (Aβ) protein, and (4) α-synuclein aggregation. Cholesterol, a substance crucial for the brain, can lead to diseases like Alzheimer’s and Parkinson’s when imbalanced. This review investigates how this imbalance causes brain cell degeneration, focusing on issues like communication breakdown and harmful protein build-up. The study combines findings from different experiments to understand cholesterol’s role in the brain. The review emphasizes the need for cholesterol balance for brain health and identifies potential treatment targets for neurodegenerative diseases. The main findings suggest that cholesterol imbalance disrupts brain cell communication and leads to harmful protein build-up, causing brain cell degeneration. The researchers conclude that focusing on cholesterol metabolism and distribution could lead to new treatments for these conditions. Future research may lead to treatments that correct cholesterol imbalances, possibly slowing or preventing neurodegenerative diseases. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1685-1690"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01273-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A neutrophil elastase-generated mature form of IL-33 is a potent regulator of endothelial cell activation and proliferative retinopathy 中性粒细胞弹性蛋白酶生成的成熟形式 IL-33 是内皮细胞活化和增殖性视网膜病变的有效调节剂。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01279-y
Shivantika Bisen, Shailendra Kumar Verma, Chandra Sekhar Mukhopadhyay, Nikhlesh K. Singh
Human interleukin-33 (IL-33) is a 270 amino acid protein that belongs to the IL-1 cytokine family and plays an important role in various inflammatory disorders. Neutrophil proteases (Cathepsin G and Elastase) and mast cell proteases (tryptase and chymase) regulate the activity of IL-33 by processing full-length IL-33 into its mature form. There is little evidence on the role of these mature forms of IL-33 in retinal endothelial cell signaling and pathological retinal angiogenesis. Here, we cloned, expressed, and purified the various mature forms of human IL-33 and then evaluated the effects of IL-3395-270, IL-3399-270, IL-33109-270, and IL-33112-270 on angiogenesis in human retinal microvascular endothelial cells (HRMVECs). We observed that IL-3395-270, IL-3399-270, IL-33109-270, and IL-33112-270 significantly induced HRMVEC migration, tube formation and sprouting angiogenesis. However, only IL-3399-270 could induce HRMVEC proliferation. We used a murine model of oxygen-induced retinopathy (OIR) to assess the role of these mature forms of IL-33 in pathological retinal neovascularization. Our 3′-mRNA sequencing and signaling studies indicated that IL-3399-270 and IL-33109-270 were more potent at inducing endothelial cell activation and angiogenesis than the other mature forms. We found that genetic deletion of IL-33 significantly reduced OIR-induced retinal neovascularization in the mouse retina and that intraperitoneal administration of mature forms of IL-33, mainly IL-3399–270 and IL-33109–270, significantly restored ischemia-induced angiogenic sprouting and tuft formation in the hypoxic retinas of IL-33–/– mice. Thus, our study results suggest that blockade or inhibition of IL-33 cleavage by neutrophil proteases could help mitigate pathological angiogenesis in proliferative retinopathies. Interleukin-33 plays a role in many diseases and biological processes. This study investigates how various IL-33 mature forms affects blood vessel creation in the eye, especially in eye diseases. The researchers used genetic and drug-related methods to study the effects of IL-33 on blood vessel formation in the eye, focusing on how it regulates cellular signaling. The research used both in vitro and in vivo methods to understand IL-33’s role in abnormal blood vessel growth, specifically in oxygen-induced eye disease, a model for diseases like premature retinopathy and some aspects of diabetic retinopathy. The research concludes that IL-33, especially its enzyme-processed forms, plays a key role in the development of proliferative retinopathies by promoting abnormal blood vessel growth in the eye. This new understanding of IL-33’s function could lead to new treatments for proliferative retinopathies. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
人白细胞介素-33(IL-33)是一种 270 个氨基酸的蛋白质,属于 IL-1 细胞因子家族,在各种炎症性疾病中发挥着重要作用。中性粒细胞蛋白酶(凝血酶 G 和弹性蛋白酶)和肥大细胞蛋白酶(胰蛋白酶和糜蛋白酶)通过将全长 IL-33 加工成成熟形式来调节 IL-33 的活性。关于这些成熟形式的 IL-33 在视网膜内皮细胞信号传导和病理性视网膜血管生成中的作用,目前还没有什么证据。在这里,我们克隆、表达和纯化了人IL-33的各种成熟形式,然后评估了IL-3395-270、IL-3399-270、IL-33109-270和IL-33112-270对人视网膜微血管内皮细胞(HRMVECs)血管生成的影响。我们观察到,IL-3395-270、IL-3399-270、IL-33109-270 和 IL-33112-270 能显著诱导 HRMVEC 迁移、管形成和芽状血管生成。然而,只有 IL-3399-270 能诱导 HRMVEC 增殖。我们利用小鼠氧诱导视网膜病变(OIR)模型来评估这些成熟形式的 IL-33 在病理性视网膜新生血管中的作用。我们的 3'-mRNA 测序和信号研究表明,IL-3399-270 和 IL-33109-270 在诱导内皮细胞活化和血管生成方面比其他成熟形式的 IL-33 更有效。我们发现,基因缺失 IL-33 能显著减少 OIR 诱导的小鼠视网膜新生血管,而腹腔注射成熟形式的 IL-33,主要是 IL-3399-270 和 IL-33109-270,能显著恢复缺血诱导的血管新生萌芽和 IL-33-/- 小鼠缺氧视网膜中的血管丛形成。因此,我们的研究结果表明,阻断或抑制中性粒细胞蛋白酶对IL-33的裂解有助于缓解增殖性视网膜病变中的病理性血管生成。
{"title":"A neutrophil elastase-generated mature form of IL-33 is a potent regulator of endothelial cell activation and proliferative retinopathy","authors":"Shivantika Bisen, Shailendra Kumar Verma, Chandra Sekhar Mukhopadhyay, Nikhlesh K. Singh","doi":"10.1038/s12276-024-01279-y","DOIUrl":"10.1038/s12276-024-01279-y","url":null,"abstract":"Human interleukin-33 (IL-33) is a 270 amino acid protein that belongs to the IL-1 cytokine family and plays an important role in various inflammatory disorders. Neutrophil proteases (Cathepsin G and Elastase) and mast cell proteases (tryptase and chymase) regulate the activity of IL-33 by processing full-length IL-33 into its mature form. There is little evidence on the role of these mature forms of IL-33 in retinal endothelial cell signaling and pathological retinal angiogenesis. Here, we cloned, expressed, and purified the various mature forms of human IL-33 and then evaluated the effects of IL-3395-270, IL-3399-270, IL-33109-270, and IL-33112-270 on angiogenesis in human retinal microvascular endothelial cells (HRMVECs). We observed that IL-3395-270, IL-3399-270, IL-33109-270, and IL-33112-270 significantly induced HRMVEC migration, tube formation and sprouting angiogenesis. However, only IL-3399-270 could induce HRMVEC proliferation. We used a murine model of oxygen-induced retinopathy (OIR) to assess the role of these mature forms of IL-33 in pathological retinal neovascularization. Our 3′-mRNA sequencing and signaling studies indicated that IL-3399-270 and IL-33109-270 were more potent at inducing endothelial cell activation and angiogenesis than the other mature forms. We found that genetic deletion of IL-33 significantly reduced OIR-induced retinal neovascularization in the mouse retina and that intraperitoneal administration of mature forms of IL-33, mainly IL-3399–270 and IL-33109–270, significantly restored ischemia-induced angiogenic sprouting and tuft formation in the hypoxic retinas of IL-33–/– mice. Thus, our study results suggest that blockade or inhibition of IL-33 cleavage by neutrophil proteases could help mitigate pathological angiogenesis in proliferative retinopathies. Interleukin-33 plays a role in many diseases and biological processes. This study investigates how various IL-33 mature forms affects blood vessel creation in the eye, especially in eye diseases. The researchers used genetic and drug-related methods to study the effects of IL-33 on blood vessel formation in the eye, focusing on how it regulates cellular signaling. The research used both in vitro and in vivo methods to understand IL-33’s role in abnormal blood vessel growth, specifically in oxygen-induced eye disease, a model for diseases like premature retinopathy and some aspects of diabetic retinopathy. The research concludes that IL-33, especially its enzyme-processed forms, plays a key role in the development of proliferative retinopathies by promoting abnormal blood vessel growth in the eye. This new understanding of IL-33’s function could lead to new treatments for proliferative retinopathies. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1703-1716"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01279-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unique expression and critical role of metallothionein 3 in the control of osteoclastogenesis and osteoporosis 金属硫蛋白 3 在控制破骨细胞生成和骨质疏松症中的独特表达和关键作用。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01290-3
Shenzheng Mo, Min Kyung Kim, Ji Sun Jang, Seung Hye Lee, Seo Jin Hong, Suhan Jung, Hong-Hee Kim
Bone homeostasis is maintained by an intricate balance between osteoclasts and osteoblasts, which becomes disturbed in osteoporosis. Metallothioneins (MTs) are major contributors in cellular zinc regulation. However, the role of MTs in bone cell regulation has remained unexplored. Single-cell RNA sequencing analysis discovered that, unlike the expression of other MT members, the expression of MT3 was unique to osteoclasts among various macrophage populations and was highly upregulated during osteoclast differentiation. This unique MT3 upregulation was validated experimentally and supported by ATAC sequencing data analyses. Downregulation of MT3 by gene knockdown or knockout resulted in excessive osteoclastogenesis and exacerbated bone loss in ovariectomy-induced osteoporosis. Transcriptome sequencing of MT3 knockdown osteoclasts and gene set enrichment analysis indicated that the oxidative stress and redox pathways were enriched, which was verified by MT3-dependent regulation of reactive oxygen species (ROS). In addition, MT3 deficiency increased the transcriptional activity of SP1 in a manner dependent on intracellular zinc levels. This MT3-zinc-SP1 axis was crucial for the control of osteoclasts, as zinc chelation and SP1 knockdown abrogated the promotion of SP1 activity and osteoclastogenesis by MT3 deletion. Moreover, SP1 bound to the NFATc1 promoter, and overexpression of an inactive SP1 mutant negated the effects of MT3 deletion on NFATc1 and osteoclastogenesis. In conclusion, MT3 plays a pivotal role in controlling osteoclastogenesis and bone metabolism via dual axes involving ROS and SP1. The present study demonstrated that MT3 elevation is a potential therapeutic strategy for osteolytic bone disorders, and it established for the first time that MT3 is a crucial bone mass regulator. Bone diseases such as osteoporosis often result from imbalances in bone remodeling, a process involving bone breakdown by cells called osteoclasts and formation by cells called osteoblasts. This study examines the role of Metallothionein 3, a protein that binds to zinc, in osteoclasts. Using a mix of single-cell RNA sequencing database and knockout mouse models, the study investigates how MT3 affects osteoclast development and activity. The researchers used various methods, including gene knockdown and overexpression techniques, to alter MT3 levels in cells and observed the effects on osteoclast formation and bone breakdown. The results indicate that MT3 inhibits osteoclast development and decreases bone loss, suggesting its potential as a treatment target for bone diseases. The study concludes that MT3 plays a crucial role in bone remodeling by controlling osteoclast activity. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
骨平衡由破骨细胞和成骨细胞之间错综复杂的平衡来维持,而骨质疏松症会破坏这种平衡。金属硫蛋白(MTs)是细胞锌调节的主要成分。然而,MTs 在骨细胞调控中的作用仍未得到探索。单细胞 RNA 测序分析发现,与其他 MT 成员的表达不同,在各种巨噬细胞群中,破骨细胞独有 MT3 的表达,并且在破骨细胞分化过程中高度上调。这种独特的 MT3 上调得到了实验验证和 ATAC 测序数据分析的支持。在卵巢切除术诱导的骨质疏松症中,通过基因敲除或基因敲除下调 MT3 会导致过度的破骨细胞生成并加剧骨质流失。MT3基因敲除破骨细胞的转录组测序和基因组富集分析表明,氧化应激和氧化还原通路被富集,这一点通过MT3对活性氧(ROS)的依赖性调控得到了验证。此外,MT3 的缺乏增加了 SP1 的转录活性,其方式依赖于细胞内的锌水平。MT3-锌-SP1轴对破骨细胞的控制至关重要,因为锌螯合和SP1敲除会减弱MT3缺失对SP1活性和破骨细胞生成的促进作用。此外,SP1与NFATc1启动子结合,过表达无活性的SP1突变体可抵消MT3缺失对NFATc1和破骨细胞生成的影响。总之,MT3通过涉及ROS和SP1的双轴在控制破骨细胞生成和骨代谢中起着关键作用。本研究表明,MT3的升高是溶骨性骨病的一种潜在治疗策略,并首次证实了MT3是一种关键的骨量调节因子。
{"title":"Unique expression and critical role of metallothionein 3 in the control of osteoclastogenesis and osteoporosis","authors":"Shenzheng Mo, Min Kyung Kim, Ji Sun Jang, Seung Hye Lee, Seo Jin Hong, Suhan Jung, Hong-Hee Kim","doi":"10.1038/s12276-024-01290-3","DOIUrl":"10.1038/s12276-024-01290-3","url":null,"abstract":"Bone homeostasis is maintained by an intricate balance between osteoclasts and osteoblasts, which becomes disturbed in osteoporosis. Metallothioneins (MTs) are major contributors in cellular zinc regulation. However, the role of MTs in bone cell regulation has remained unexplored. Single-cell RNA sequencing analysis discovered that, unlike the expression of other MT members, the expression of MT3 was unique to osteoclasts among various macrophage populations and was highly upregulated during osteoclast differentiation. This unique MT3 upregulation was validated experimentally and supported by ATAC sequencing data analyses. Downregulation of MT3 by gene knockdown or knockout resulted in excessive osteoclastogenesis and exacerbated bone loss in ovariectomy-induced osteoporosis. Transcriptome sequencing of MT3 knockdown osteoclasts and gene set enrichment analysis indicated that the oxidative stress and redox pathways were enriched, which was verified by MT3-dependent regulation of reactive oxygen species (ROS). In addition, MT3 deficiency increased the transcriptional activity of SP1 in a manner dependent on intracellular zinc levels. This MT3-zinc-SP1 axis was crucial for the control of osteoclasts, as zinc chelation and SP1 knockdown abrogated the promotion of SP1 activity and osteoclastogenesis by MT3 deletion. Moreover, SP1 bound to the NFATc1 promoter, and overexpression of an inactive SP1 mutant negated the effects of MT3 deletion on NFATc1 and osteoclastogenesis. In conclusion, MT3 plays a pivotal role in controlling osteoclastogenesis and bone metabolism via dual axes involving ROS and SP1. The present study demonstrated that MT3 elevation is a potential therapeutic strategy for osteolytic bone disorders, and it established for the first time that MT3 is a crucial bone mass regulator. Bone diseases such as osteoporosis often result from imbalances in bone remodeling, a process involving bone breakdown by cells called osteoclasts and formation by cells called osteoblasts. This study examines the role of Metallothionein 3, a protein that binds to zinc, in osteoclasts. Using a mix of single-cell RNA sequencing database and knockout mouse models, the study investigates how MT3 affects osteoclast development and activity. The researchers used various methods, including gene knockdown and overexpression techniques, to alter MT3 levels in cells and observed the effects on osteoclast formation and bone breakdown. The results indicate that MT3 inhibits osteoclast development and decreases bone loss, suggesting its potential as a treatment target for bone diseases. The study concludes that MT3 plays a crucial role in bone remodeling by controlling osteoclast activity. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1791-1806"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01290-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Astrocytic 5-HT1A receptor mediates age-dependent hippocampal LTD and fear memory extinction in male mice 星形胶质细胞 5-HT1A 受体介导雄性小鼠年龄依赖性海马 LTD 和恐惧记忆的消退
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01285-0
Qian-Yun Wu, Lian-Hong Lin, Kun Lu, Si-Fu Deng, Wei-Min Li, Yuan Xu, Bin Zhang, Ji-Hong Liu
NMDA receptor-dependent long-term depression (LTD) in the hippocampus is a well-known form of synaptic plasticity that has been linked to different cognitive functions. Although the underlying mechanisms remain unclear, this form of LTD cannot be induced by low-frequency stimulation (LFS) in adult mice. In this study, we found that LFS-induced LTD was not easily induced in adult animals and was age dependent. Interestingly, the level of the 5-HT1A receptor was correspondingly increased and exhibited an inverse correlation with the magnitude of LFS-LTD during development. Knockout or pharmacological inhibition of the 5-HT1A receptor reversed impaired LFS-LTD in adult mice (P60), while activation or inhibition of this receptor disturbed or enhanced LFS-LTD in adolescent mice (P21), respectively. Furthermore, the astrocytic 5-HT1A receptor in the hippocampus predominantly mediated age-dependent LFS-LTD through enhancing GABAergic neurotransmission. Finally, fear memory extinction differed among the above conditions. These observations enrich our knowledge of LTD at the cellular level and suggest a therapeutic approach for LTD-related psychiatric disorders. Understanding how our brains learn and remember is intriguing. As we age, our learning and memory abilities can alter, and scientists are trying to understand why. A recent study investigates this by studying a specific brain receptor, the 5-HT1A receptor, and its effect on learning and memory in mice. The team focused on a process called long-term depression. They found that the ability to induce LTD changes with age and that the 5-HT1A receptor plays a key role in this. They discovered that the activity of 5-HT1A receptors in certain brain cells, astrocytes, is necessary for LTD and influences fear memory extinction. The researchers conclude that the 5-HT1A receptor in astrocytes plays a crucial role in regulating learning and memory processes related to LTD. This discovery could lead to new treatments for memory-related disorders. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
海马中的 NMDA 受体依赖性长期抑制(LTD)是一种众所周知的突触可塑性形式,与不同的认知功能有关。虽然其潜在机制尚不清楚,但这种形式的LTD在成年小鼠中无法通过低频刺激(LFS)诱导。在这项研究中,我们发现低频刺激诱导的LTD在成年动物中不易诱导,而且与年龄有关。有趣的是,在发育过程中,5-HT1A 受体的水平相应升高,并与 LFS-LTD 的程度呈反相关。敲除或药物抑制 5-HT1A 受体可逆转成年小鼠(P60)受损的 LFS-LTD,而激活或抑制该受体可分别干扰或增强青少年小鼠(P21)的 LFS-LTD。此外,海马中星形胶质细胞的5-HT1A受体主要通过增强GABA能神经递质介导年龄依赖性LFS-LTD。最后,恐惧记忆的消退在上述条件下有所不同。这些观察结果丰富了我们对细胞水平LTD的认识,并为LTD相关精神疾病的治疗提供了思路。
{"title":"Astrocytic 5-HT1A receptor mediates age-dependent hippocampal LTD and fear memory extinction in male mice","authors":"Qian-Yun Wu, Lian-Hong Lin, Kun Lu, Si-Fu Deng, Wei-Min Li, Yuan Xu, Bin Zhang, Ji-Hong Liu","doi":"10.1038/s12276-024-01285-0","DOIUrl":"10.1038/s12276-024-01285-0","url":null,"abstract":"NMDA receptor-dependent long-term depression (LTD) in the hippocampus is a well-known form of synaptic plasticity that has been linked to different cognitive functions. Although the underlying mechanisms remain unclear, this form of LTD cannot be induced by low-frequency stimulation (LFS) in adult mice. In this study, we found that LFS-induced LTD was not easily induced in adult animals and was age dependent. Interestingly, the level of the 5-HT1A receptor was correspondingly increased and exhibited an inverse correlation with the magnitude of LFS-LTD during development. Knockout or pharmacological inhibition of the 5-HT1A receptor reversed impaired LFS-LTD in adult mice (P60), while activation or inhibition of this receptor disturbed or enhanced LFS-LTD in adolescent mice (P21), respectively. Furthermore, the astrocytic 5-HT1A receptor in the hippocampus predominantly mediated age-dependent LFS-LTD through enhancing GABAergic neurotransmission. Finally, fear memory extinction differed among the above conditions. These observations enrich our knowledge of LTD at the cellular level and suggest a therapeutic approach for LTD-related psychiatric disorders. Understanding how our brains learn and remember is intriguing. As we age, our learning and memory abilities can alter, and scientists are trying to understand why. A recent study investigates this by studying a specific brain receptor, the 5-HT1A receptor, and its effect on learning and memory in mice. The team focused on a process called long-term depression. They found that the ability to induce LTD changes with age and that the 5-HT1A receptor plays a key role in this. They discovered that the activity of 5-HT1A receptors in certain brain cells, astrocytes, is necessary for LTD and influences fear memory extinction. The researchers conclude that the 5-HT1A receptor in astrocytes plays a crucial role in regulating learning and memory processes related to LTD. This discovery could lead to new treatments for memory-related disorders. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1763-1775"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01285-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tailored antisense oligonucleotides designed to correct aberrant splicing reveal actionable groups of mutations for rare genetic disorders 为纠正异常剪接而设计的定制反义寡核苷酸揭示了罕见遗传疾病的可操作突变群。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01292-1
Htoo A. Wai, Eliska Svobodova, Natalia Romero Herrera, Andrew G. L. Douglas, John W. Holloway, Francisco E. Baralle, Marco Baralle, Diana Baralle
Effective translation of rare disease diagnosis knowledge into therapeutic applications is achievable within a reasonable timeframe; where mutations are amenable to current antisense oligonucleotide technology. In our study, we identified five distinct types of abnormal splice-causing mutations in patients with rare genetic disorders and developed a tailored antisense oligonucleotide for each mutation type using phosphorodiamidate morpholino oligomers with or without octa-guanidine dendrimers and 2′-O-methoxyethyl phosphorothioate. We observed variations in treatment effects and efficiencies, influenced by both the chosen chemistry and the specific nature of the aberrant splicing patterns targeted for correction. Our study demonstrated the successful correction of all five different types of aberrant splicing. Our findings reveal that effective correction of aberrant splicing can depend on altering the chemical composition of oligonucleotides and suggest a fast, efficient, and feasible approach for developing personalized therapeutic interventions for genetic disorders within short time frames. Millions globally suffer from rare diseases, often genetic and affecting children. This study explores using antisense oligonucleotides to fix incorrect RNA splicing, a common result of disease-causing genetic mutations. The results showed that tailored ASOs could correct incorrect splicing for various mutation types, showing this technology′s potential in treating rare genetic diseases. The team chose five mutation types disrupting normal splicing and created specific ASOs to correct these errors in cell models. They created minigenes to simulate the mutations and tested different ASOs′ effectiveness. This method was key to understanding ASOs′ ability to restore normal gene function, crucial for developing targeted treatments for rare genetic disorders. This research could lead to new, targeted treatments for rare genetic disorders, offering hope to millions of patients and their families facing limited treatment options. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
将罕见疾病诊断知识有效地转化为治疗应用可以在合理的时间范围内实现;如果突变适合当前的反义寡核苷酸技术。在我们的研究中,我们在罕见遗传疾病患者中发现了五种不同类型的异常剪接致突变,并针对每种突变类型,使用含或不含八胍树枝状聚合物和 2'-O-methoxyethyl phosphorothioate 的磷酸二铵吗啉寡核苷酸,开发了一种量身定制的反义寡核苷酸。我们观察到处理效果和效率的变化,这既受所选化学成分的影响,也受要校正的异常剪接模式的具体性质的影响。我们的研究表明,所有五种不同类型的异常剪接都能成功纠正。我们的研究结果表明,对异常剪接的有效校正可以依赖于改变寡核苷酸的化学成分,并提出了一种快速、高效、可行的方法,用于在短时间内开发针对遗传疾病的个性化治疗干预措施。
{"title":"Tailored antisense oligonucleotides designed to correct aberrant splicing reveal actionable groups of mutations for rare genetic disorders","authors":"Htoo A. Wai, Eliska Svobodova, Natalia Romero Herrera, Andrew G. L. Douglas, John W. Holloway, Francisco E. Baralle, Marco Baralle, Diana Baralle","doi":"10.1038/s12276-024-01292-1","DOIUrl":"10.1038/s12276-024-01292-1","url":null,"abstract":"Effective translation of rare disease diagnosis knowledge into therapeutic applications is achievable within a reasonable timeframe; where mutations are amenable to current antisense oligonucleotide technology. In our study, we identified five distinct types of abnormal splice-causing mutations in patients with rare genetic disorders and developed a tailored antisense oligonucleotide for each mutation type using phosphorodiamidate morpholino oligomers with or without octa-guanidine dendrimers and 2′-O-methoxyethyl phosphorothioate. We observed variations in treatment effects and efficiencies, influenced by both the chosen chemistry and the specific nature of the aberrant splicing patterns targeted for correction. Our study demonstrated the successful correction of all five different types of aberrant splicing. Our findings reveal that effective correction of aberrant splicing can depend on altering the chemical composition of oligonucleotides and suggest a fast, efficient, and feasible approach for developing personalized therapeutic interventions for genetic disorders within short time frames. Millions globally suffer from rare diseases, often genetic and affecting children. This study explores using antisense oligonucleotides to fix incorrect RNA splicing, a common result of disease-causing genetic mutations. The results showed that tailored ASOs could correct incorrect splicing for various mutation types, showing this technology′s potential in treating rare genetic diseases. The team chose five mutation types disrupting normal splicing and created specific ASOs to correct these errors in cell models. They created minigenes to simulate the mutations and tested different ASOs′ effectiveness. This method was key to understanding ASOs′ ability to restore normal gene function, crucial for developing targeted treatments for rare genetic disorders. This research could lead to new, targeted treatments for rare genetic disorders, offering hope to millions of patients and their families facing limited treatment options. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1816-1825"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01292-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-level brain somatic mutations in exonic regions are collectively implicated in autism with germline mutations in autism risk genes 外显子区域的低水平脑体细胞突变与自闭症风险基因的种系突变共同牵涉到自闭症。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01284-1
Il Bin Kim, Myeong-Heui Kim, Saehoon Jung, Woo Kyeong Kim, Junehawk Lee, Young Seok Ju, Maree J. Webster, Sanghyeon Kim, Ja Hye Kim, Hyun Jung Kim, Junho Kim, Sangwoo Kim, Jeong Ho Lee
Low-level somatic mutations in the human brain are implicated in various neurological disorders. The contribution of low-level brain somatic mutations to autism spectrum disorder (ASD), however, remains poorly understood. Here, we performed high-depth exome sequencing with an average read depth of 559.3x in 181 cortical, cerebellar, and peripheral tissue samples to identify brain somatic single nucleotide variants (SNVs) in 24 ASD subjects and 31 controls. We detected ~2.4 brain somatic SNVs per exome per single brain region, with a variant allele frequency (VAF) as low as 0.3%. The mutational profiles, including the number, signature, and type, were not significantly different between the ASD patients and controls. Intriguingly, when considering genes with low-level brain somatic SNVs and ASD risk genes with damaging germline SNVs together, the merged set of genes carrying either somatic or germline SNVs in ASD patients was significantly involved in ASD-associated pathophysiology, including dendrite spine morphogenesis (p = 0.025), mental retardation (p = 0.012), and intrauterine growth retardation (p = 0.012). Additionally, the merged gene set showed ASD-associated spatiotemporal expression in the early and mid-fetal cortex, striatum, and thalamus (all p < 0.05). Patients with damaging mutations in the merged gene set had a greater ASD risk than did controls (odds ratio = 3.92, p = 0.025, 95% confidence interval = 1.12–14.79). The findings of this study suggest that brain somatic SNVs and germline SNVs may collectively contribute to ASD-associated pathophysiology. Autism Spectrum Disorder is a complex condition influenced by various genetic factors, including inherited traits and new changes in genes. This study investigates the role of low-level brain somatic mutations in ASD. The researchers analyzed brain tissues from deceased individuals, both with and without ASD, using high-depth whole-exome sequencing. The results showed that low-level brain somatic mutations, along with inherited genetic variations, contribute to ASD’s genetic makeup. These mutations were found in genes linked to brain development and function. The study emphasizes the need to consider both inherited and somatic mutations to understand ASD’s genetic complexity. Researchers conclude that the interaction between somatic and inherited mutations is crucial in ASD, providing new insights into its genetic basis. This study enhances our understanding of ASD’s genetic diversity and suggests a multifaceted genetic contribution to the disorder. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
人脑中的低水平体细胞突变与各种神经系统疾病有关。然而,人们对低水平大脑体细胞突变对自闭症谱系障碍(ASD)的影响仍然知之甚少。在这里,我们对 181 份皮层、小脑和外周组织样本进行了平均读取深度为 559.3 倍的高深度外显子测序,以鉴定 24 名 ASD 受试者和 31 名对照者的脑体细胞单核苷酸变异(SNVs)。我们在每个脑区的每个外显子组检测到约 2.4 个脑部体细胞 SNV,变异等位基因频率 (VAF) 低至 0.3%。ASD患者和对照组的突变特征,包括数量、特征和类型,均无显著差异。耐人寻味的是,当把低水平脑部体细胞SNV基因和具有破坏性种系SNV基因的ASD风险基因放在一起考虑时,ASD患者中携带体细胞或种系SNV基因的合并基因集明显参与了ASD相关的病理生理学,包括树突棘形态发生(p = 0.025)、智力迟钝(p = 0.012)和宫内生长迟缓(p = 0.012)。此外,合并后的基因组在胎儿早期和中期皮层、纹状体和丘脑中显示出与 ASD 相关的时空表达(均 p = 0.025)。
{"title":"Low-level brain somatic mutations in exonic regions are collectively implicated in autism with germline mutations in autism risk genes","authors":"Il Bin Kim,&nbsp;Myeong-Heui Kim,&nbsp;Saehoon Jung,&nbsp;Woo Kyeong Kim,&nbsp;Junehawk Lee,&nbsp;Young Seok Ju,&nbsp;Maree J. Webster,&nbsp;Sanghyeon Kim,&nbsp;Ja Hye Kim,&nbsp;Hyun Jung Kim,&nbsp;Junho Kim,&nbsp;Sangwoo Kim,&nbsp;Jeong Ho Lee","doi":"10.1038/s12276-024-01284-1","DOIUrl":"10.1038/s12276-024-01284-1","url":null,"abstract":"Low-level somatic mutations in the human brain are implicated in various neurological disorders. The contribution of low-level brain somatic mutations to autism spectrum disorder (ASD), however, remains poorly understood. Here, we performed high-depth exome sequencing with an average read depth of 559.3x in 181 cortical, cerebellar, and peripheral tissue samples to identify brain somatic single nucleotide variants (SNVs) in 24 ASD subjects and 31 controls. We detected ~2.4 brain somatic SNVs per exome per single brain region, with a variant allele frequency (VAF) as low as 0.3%. The mutational profiles, including the number, signature, and type, were not significantly different between the ASD patients and controls. Intriguingly, when considering genes with low-level brain somatic SNVs and ASD risk genes with damaging germline SNVs together, the merged set of genes carrying either somatic or germline SNVs in ASD patients was significantly involved in ASD-associated pathophysiology, including dendrite spine morphogenesis (p = 0.025), mental retardation (p = 0.012), and intrauterine growth retardation (p = 0.012). Additionally, the merged gene set showed ASD-associated spatiotemporal expression in the early and mid-fetal cortex, striatum, and thalamus (all p &lt; 0.05). Patients with damaging mutations in the merged gene set had a greater ASD risk than did controls (odds ratio = 3.92, p = 0.025, 95% confidence interval = 1.12–14.79). The findings of this study suggest that brain somatic SNVs and germline SNVs may collectively contribute to ASD-associated pathophysiology. Autism Spectrum Disorder is a complex condition influenced by various genetic factors, including inherited traits and new changes in genes. This study investigates the role of low-level brain somatic mutations in ASD. The researchers analyzed brain tissues from deceased individuals, both with and without ASD, using high-depth whole-exome sequencing. The results showed that low-level brain somatic mutations, along with inherited genetic variations, contribute to ASD’s genetic makeup. These mutations were found in genes linked to brain development and function. The study emphasizes the need to consider both inherited and somatic mutations to understand ASD’s genetic complexity. Researchers conclude that the interaction between somatic and inherited mutations is crucial in ASD, providing new insights into its genetic basis. This study enhances our understanding of ASD’s genetic diversity and suggests a multifaceted genetic contribution to the disorder. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1750-1762"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01284-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutrophil extracellular traps mediate the crosstalk between plaque microenvironment and unstable carotid plaque formation 中性粒细胞胞外捕获器介导斑块微环境与不稳定颈动脉斑块形成之间的相互影响。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01281-4
Yu Cao, Minghui Chen, Xinyu Jiao, Shuijie Li, Dong Wang, Yongxuan Zhan, Jiaju Li, Zhongfei Hao, Qingbin Li, Yang Liu, Yan Feng, Ruiyan Li, Hongjun Wang, Mingli Liu, Qiang Fu, Yongli Li
The development of unstable carotid atherosclerotic plaques is associated with the induction of neutrophil extracellular traps (NETs) via the activation of diverse inflammatory mediators in the circulating bloodstream. However, the underlying mechanisms through which NETs influence the microenvironment of atherosclerotic plaques and contribute to the development of unstable carotid plaques remain largely elusive. The objective of this study was to elucidate the role of myeloid differentiation protein 1 (MD-1, LY86)-induced NETs underlying the crosstalk between unstable plaque formation and the plaque microenvironment. We employed bioinformatics analysis to identify key genes associated with carotid-unstable plaque, followed by comprehensive validation using various experimental approaches on tissue specimens and plasma samples classified based on pathological characteristics. Patients with carotid-unstable plaques exhibited elevated plasma concentrations of MD-1 (LY86), while patients with stable plaques demonstrated comparatively lower levels. Furthermore, soluble MD-1 was found to induce the formation of NETs through activation of Toll-like receptor signaling pathway. The proliferative and immature vascularization effects of NETs on endothelial cells, as well as their inhibitory impact on cell migration, are directly correlated with the concentration of NETs. Additionally, NETs were found to activate the NF-κB signaling pathway, thereby upregulating ICAM1, VCAM1, MMP14, VEGFA, and IL6 expression in both Human umbilical vein endothelial cells (HUVECs) and HAECs. Subsequently, a significant increase in intraplaque neovascularization by NETs results in poor carotid plaque stability, and NETs in turn stimulate macrophages to produce more MD-1, generating a harmful positive feedback loop. Our findings suggest that soluble MD-1 in the bloodstream triggers the production of NETs through activation of the Toll-like receptor signaling pathway and further indicate NETs mediate a crosstalk between the microenvironment of the carotid plaque and the neovascularization of the intraplaque region. Inhibiting NETs formation or MD-1 secretion may represent a promising strategy to effectively suppress the development of unstable carotid plaques. Atherosclerosis, a disease where arteries get blocked with fat, is a main cause of heart disease and stroke. Predicting which atherosclerotic plaques will cause heart attacks is hard. Researchers analyzed gene data from unstable and stable carotid plaques, focusing on neutrophils and a protein called MD-1. The study involved 30 patients and 10 healthy volunteers to understand how MD-1 and neutrophils contribute to plaque instability. The main finding is that MD-1 could be a biomarker for unstable plaques, offering a new target for therapies to prevent major heart events. This progress in understanding the molecular mechanisms behind plaque instability could lead to better prevention strategies for heart disease. Future re
不稳定颈动脉粥样硬化斑块的形成与中性粒细胞胞外捕获物(NET)通过激活循环血液中的多种炎症介质诱导有关。然而,NETs 影响动脉粥样硬化斑块的微环境并导致不稳定颈动脉斑块发展的潜在机制在很大程度上仍然难以捉摸。本研究的目的是阐明髓系分化蛋白1(MD-1,LY86)诱导的NET在不稳定斑块形成和斑块微环境之间的相互作用。我们采用生物信息学分析方法确定了与颈动脉不稳定斑块相关的关键基因,然后利用各种实验方法对根据病理特征分类的组织标本和血浆样本进行了全面验证。颈动脉不稳定斑块患者的血浆中MD-1(LY86)浓度升高,而稳定斑块患者的浓度相对较低。此外,研究还发现可溶性 MD-1 可通过激活 Toll 样受体信号通路诱导 NET 的形成。NETs对内皮细胞的增殖和未成熟血管形成作用以及对细胞迁移的抑制作用与NETs的浓度直接相关。此外,研究还发现 NETs 能激活 NF-κB 信号通路,从而上调 ICAM1、VCAM1、MMP14、VEGFA 和 IL6 在人脐静脉内皮细胞(HUVECs)和 HAECs 中的表达。随后,NET 导致斑块内新生血管显著增加,导致颈动脉斑块稳定性变差,NET 反过来又刺激巨噬细胞产生更多的 MD-1,从而产生有害的正反馈循环。我们的研究结果表明,血液中的可溶性MD-1通过激活Toll样受体信号通路触发NET的产生,并进一步表明NET介导了颈动脉斑块微环境与斑块内新生血管之间的串联。抑制NETs的形成或MD-1的分泌可能是有效抑制不稳定颈动脉斑块发展的一种有前途的策略。
{"title":"Neutrophil extracellular traps mediate the crosstalk between plaque microenvironment and unstable carotid plaque formation","authors":"Yu Cao,&nbsp;Minghui Chen,&nbsp;Xinyu Jiao,&nbsp;Shuijie Li,&nbsp;Dong Wang,&nbsp;Yongxuan Zhan,&nbsp;Jiaju Li,&nbsp;Zhongfei Hao,&nbsp;Qingbin Li,&nbsp;Yang Liu,&nbsp;Yan Feng,&nbsp;Ruiyan Li,&nbsp;Hongjun Wang,&nbsp;Mingli Liu,&nbsp;Qiang Fu,&nbsp;Yongli Li","doi":"10.1038/s12276-024-01281-4","DOIUrl":"10.1038/s12276-024-01281-4","url":null,"abstract":"The development of unstable carotid atherosclerotic plaques is associated with the induction of neutrophil extracellular traps (NETs) via the activation of diverse inflammatory mediators in the circulating bloodstream. However, the underlying mechanisms through which NETs influence the microenvironment of atherosclerotic plaques and contribute to the development of unstable carotid plaques remain largely elusive. The objective of this study was to elucidate the role of myeloid differentiation protein 1 (MD-1, LY86)-induced NETs underlying the crosstalk between unstable plaque formation and the plaque microenvironment. We employed bioinformatics analysis to identify key genes associated with carotid-unstable plaque, followed by comprehensive validation using various experimental approaches on tissue specimens and plasma samples classified based on pathological characteristics. Patients with carotid-unstable plaques exhibited elevated plasma concentrations of MD-1 (LY86), while patients with stable plaques demonstrated comparatively lower levels. Furthermore, soluble MD-1 was found to induce the formation of NETs through activation of Toll-like receptor signaling pathway. The proliferative and immature vascularization effects of NETs on endothelial cells, as well as their inhibitory impact on cell migration, are directly correlated with the concentration of NETs. Additionally, NETs were found to activate the NF-κB signaling pathway, thereby upregulating ICAM1, VCAM1, MMP14, VEGFA, and IL6 expression in both Human umbilical vein endothelial cells (HUVECs) and HAECs. Subsequently, a significant increase in intraplaque neovascularization by NETs results in poor carotid plaque stability, and NETs in turn stimulate macrophages to produce more MD-1, generating a harmful positive feedback loop. Our findings suggest that soluble MD-1 in the bloodstream triggers the production of NETs through activation of the Toll-like receptor signaling pathway and further indicate NETs mediate a crosstalk between the microenvironment of the carotid plaque and the neovascularization of the intraplaque region. Inhibiting NETs formation or MD-1 secretion may represent a promising strategy to effectively suppress the development of unstable carotid plaques. Atherosclerosis, a disease where arteries get blocked with fat, is a main cause of heart disease and stroke. Predicting which atherosclerotic plaques will cause heart attacks is hard. Researchers analyzed gene data from unstable and stable carotid plaques, focusing on neutrophils and a protein called MD-1. The study involved 30 patients and 10 healthy volunteers to understand how MD-1 and neutrophils contribute to plaque instability. The main finding is that MD-1 could be a biomarker for unstable plaques, offering a new target for therapies to prevent major heart events. This progress in understanding the molecular mechanisms behind plaque instability could lead to better prevention strategies for heart disease. Future re","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1717-1735"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01281-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The potential role of gut microbiota-derived metabolites as regulators of metabolic syndrome-associated mitochondrial and endolysosomal dysfunction in Alzheimer’s disease 肠道微生物群衍生代谢物作为阿尔茨海默病代谢综合征相关线粒体和内溶酶体功能障碍调节剂的潜在作用。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01282-3
Young Hyun Jung, Chang Woo Chae, Ho Jae Han
Although the role of gut microbiota (GMB)-derived metabolites in mitochondrial and endolysosomal dysfunction in Alzheimer’s disease (AD) under metabolic syndrome remains unclear, deciphering these host–metabolite interactions represents a major public health challenge. Dysfunction of mitochondria and endolysosomal networks (ELNs) plays a crucial role in metabolic syndrome and can exacerbate AD progression, highlighting the need to study their reciprocal regulation for a better understanding of how AD is linked to metabolic syndrome. Concurrently, metabolic disorders are associated with alterations in the composition of the GMB. Recent evidence suggests that changes in the composition of the GMB and its metabolites may be involved in AD pathology. This review highlights the mechanisms of metabolic syndrome-mediated AD development, focusing on the interconnected roles of mitochondrial dysfunction, ELN abnormalities, and changes in the GMB and its metabolites. We also discuss the pathophysiological role of GMB-derived metabolites, including amino acids, fatty acids, other metabolites, and extracellular vesicles, in mediating their effects on mitochondrial and ELN dysfunction. Finally, this review proposes therapeutic strategies for AD by directly modulating mitochondrial and ELN functions through targeting GMB metabolites under metabolic syndrome. Although mitochondrial and endolysosomal network (ELN) impairment in metabolic syndrome is considered a risk factor for neurodegenerative diseases, the regulatory role of gut microbiota (GMB)-derived metabolites in this dysfunction remains unclear. This research explores the roles and molecular mechanisms of mitochondrial dysfunction, ELN abnormalities, dysregulation of mitochondria-ELN crosstalk, and changes in GMB and its metabolites in metabolic syndrome, especially in relation to Alzheimer’s disease (AD). The researchers conclude by highlighting the potential of targeting GMB and its metabolites to develop new AD treatments, especially for those with metabolic syndrome. They suggest that understanding and modulating the links between gut health, mitochondrial function, and ELN activity could lead to new management strategies for AD in the context of gut microbiota and its metabolites. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
虽然肠道微生物群(GMB)产生的代谢物在代谢综合征下阿尔茨海默病(AD)的线粒体和内溶酶体功能障碍中的作用仍不清楚,但破译这些宿主-代谢物之间的相互作用是一项重大的公共卫生挑战。线粒体和内溶酶体网络(ELNs)的功能障碍在代谢综合征中起着至关重要的作用,并可加剧阿尔茨海默病的进展,这突出表明有必要研究它们之间的相互调控,以更好地了解阿尔茨海默病如何与代谢综合征联系在一起。同时,代谢紊乱与 GMB 组成的改变有关。最近的证据表明,GMB及其代谢物的组成变化可能与AD病理有关。本综述强调了代谢综合征介导的 AD 发病机制,重点是线粒体功能障碍、ELN 异常和 GMB 及其代谢物变化的相互关联作用。我们还讨论了 GMB 衍生代谢物(包括氨基酸、脂肪酸、其他代谢物和细胞外囊泡)在介导线粒体和 ELN 功能障碍方面的病理生理作用。最后,本综述提出了针对代谢综合征的 GMB 代谢物直接调节线粒体和 ELN 功能的 AD 治疗策略。
{"title":"The potential role of gut microbiota-derived metabolites as regulators of metabolic syndrome-associated mitochondrial and endolysosomal dysfunction in Alzheimer’s disease","authors":"Young Hyun Jung,&nbsp;Chang Woo Chae,&nbsp;Ho Jae Han","doi":"10.1038/s12276-024-01282-3","DOIUrl":"10.1038/s12276-024-01282-3","url":null,"abstract":"Although the role of gut microbiota (GMB)-derived metabolites in mitochondrial and endolysosomal dysfunction in Alzheimer’s disease (AD) under metabolic syndrome remains unclear, deciphering these host–metabolite interactions represents a major public health challenge. Dysfunction of mitochondria and endolysosomal networks (ELNs) plays a crucial role in metabolic syndrome and can exacerbate AD progression, highlighting the need to study their reciprocal regulation for a better understanding of how AD is linked to metabolic syndrome. Concurrently, metabolic disorders are associated with alterations in the composition of the GMB. Recent evidence suggests that changes in the composition of the GMB and its metabolites may be involved in AD pathology. This review highlights the mechanisms of metabolic syndrome-mediated AD development, focusing on the interconnected roles of mitochondrial dysfunction, ELN abnormalities, and changes in the GMB and its metabolites. We also discuss the pathophysiological role of GMB-derived metabolites, including amino acids, fatty acids, other metabolites, and extracellular vesicles, in mediating their effects on mitochondrial and ELN dysfunction. Finally, this review proposes therapeutic strategies for AD by directly modulating mitochondrial and ELN functions through targeting GMB metabolites under metabolic syndrome. Although mitochondrial and endolysosomal network (ELN) impairment in metabolic syndrome is considered a risk factor for neurodegenerative diseases, the regulatory role of gut microbiota (GMB)-derived metabolites in this dysfunction remains unclear. This research explores the roles and molecular mechanisms of mitochondrial dysfunction, ELN abnormalities, dysregulation of mitochondria-ELN crosstalk, and changes in GMB and its metabolites in metabolic syndrome, especially in relation to Alzheimer’s disease (AD). The researchers conclude by highlighting the potential of targeting GMB and its metabolites to develop new AD treatments, especially for those with metabolic syndrome. They suggest that understanding and modulating the links between gut health, mitochondrial function, and ELN activity could lead to new management strategies for AD in the context of gut microbiota and its metabolites. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1691-1702"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01282-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Insulin signaling is critical for sinoatrial node maintenance and function 作者更正:胰岛素信号对中房节点的维持和功能至关重要
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-24 DOI: 10.1038/s12276-024-01278-z
Sangmi Ock, Seong Woo Choi, Seung Hee Choi, Hyun Kang, Sung Joon Kim, Wang-Soo Lee, Jaetaek Kim
{"title":"Author Correction: Insulin signaling is critical for sinoatrial node maintenance and function","authors":"Sangmi Ock,&nbsp;Seong Woo Choi,&nbsp;Seung Hee Choi,&nbsp;Hyun Kang,&nbsp;Sung Joon Kim,&nbsp;Wang-Soo Lee,&nbsp;Jaetaek Kim","doi":"10.1038/s12276-024-01278-z","DOIUrl":"10.1038/s12276-024-01278-z","url":null,"abstract":"","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 7","pages":"1683-1683"},"PeriodicalIF":9.5,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental and Molecular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1